Ascendiant Capital Maintains Buy on AIM ImmunoTech, Lowers Price Target to $7

Benzinga Newsdesk www.benzinga.com Negative 51.2%

Neg 51.2% Neu 0% Pos 0%

Ascendiant Capital analyst Edward Woo maintains AIM ImmunoTech (AMEX:AIM) with a Buy and lowers the price target from $9 to $7.